Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Isoniazid
Drug ID BADD_D01204
Description Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status approved; investigational
ATC Code J04AC01
DrugBank ID DB00951
KEGG ID D00346
MeSH ID D007538
PubChem ID 3767
TTD Drug ID D09XQF
NDC Product Code 60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII V83O1VOZ8L
Synonyms Isoniazid | Isonicotinic Acid Hydrazide | Hydrazide, Isonicotinic Acid | Phthivazide | Phthivazid | Isonicotinic Acid Vanillylidenehydrazide | Acid Vanillylidenehydrazide, Isonicotinic | Vanillylidenehydrazide, Isonicotinic Acid | Ftivazide | Tubazide | Isonex
Chemical Information
Molecular Formula C6H7N3O
CAS Registry Number 54-85-3
SMILES C1=CN=CC=C1C(=O)NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Transaminases increased13.03.04.036--Not Available
Foetal death18.01.02.003; 08.04.01.0110.005560%
Pulmonary mass22.02.07.0040.002780%Not Available
Gaze palsy17.02.05.044; 06.05.02.0140.002780%Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.002780%Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.005560%Not Available
Drug resistance08.06.01.0050.047256%Not Available
Malnutrition14.03.02.0040.002780%Not Available
Optic neuropathy06.02.08.002; 17.04.05.0050.004170%Not Available
Abnormal behaviour19.01.01.0010.004170%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Renal injury20.01.03.015; 12.01.05.0010.002780%Not Available
Ill-defined disorder08.01.03.049--Not Available
Psychotic disorder19.03.01.0020.010841%
Renal impairment20.01.03.0100.014455%Not Available
Liver injury12.01.17.012; 09.01.07.0220.038083%Not Available
Adverse reaction08.06.01.0180.006115%Not Available
Cholestatic liver injury09.01.07.0160.004170%Not Available
Nail atrophy23.02.05.010--Not Available
Hypertransaminasaemia09.01.02.0050.002780%Not Available
Acute kidney injury20.01.03.0160.025018%
Posterior reversible encephalopathy syndrome17.13.02.0070.002780%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.139822%Not Available
Substance-induced psychotic disorder19.03.01.007; 12.03.01.0530.021126%Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.075053%Not Available
Autoimmune haemolytic anaemia10.04.01.005; 01.06.01.0040.004170%Not Available
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Alcohol interaction08.06.03.003--Not Available
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.002780%Not Available
IgA nephropathy20.05.01.016; 10.02.01.0630.004170%Not Available
The 10th Page    First    Pre   10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene